Eli Lilly Articles
Regulatory briefs on Bayer's Stivarga, Boehringer/Lilly's empagliflozin and Pfizer's Xeljanz
26 March 2013
Lilly's ED drug Cialis meets endpoint in LUTS/BPH study
19 March 2013
NICE draft guidance rejects Eli Lilly's Alimta for NSCLC maintenance
22 February 2013
Study finds "Big Pharma" fails at self-policing ED drug advertising
18 February 2013
Eli Lilly posts sales and EPS declines for 4th-qtr and full year 2012, but beats forecasts
30 January 2013
Bayer's Nexavar continues to dominate advanced liver cancer therapy, as other late-stage trials fail
17 January 2013
Patient trust in drugmakers declining, new report shows
14 January 2013
Lilly and Boehringer adjust LY2605541 deal; announce positive Ph III data for empagliflozin
8 January 2013
Eli Lilly financial guidance beats expectations
7 January 2013
EMA starts review of Merck & Co's cholesterol drug Tredaptive
24 December 2012
Nexavar use in Chinese patients nearly doubled in 2012
19 December 2012
Eli Lilly drops one tabalumab trial for RA
14 December 2012
Once again, no proof of added benefit found for Boehringer/Lilly's Trajenta by Germany's IQWiG
13 December 2012
Lilly plans new trial of Alzheimer's hope solanezumab
13 December 2012
Eli Lilly and Chugai to stop co-marketing of Evista in Japan
5 November 2012
News briefs: Eli Lilly expands insulin facility; and Sanofi criticized over Lemtrada
2 November 2012
European Commission approves Lilly's Cialis for BPH
31 October 2012
ASBMR 2012: Anabolics and post-marketing studies
25 October 2012
Eli Lilly 3rd-qtr 2012 sales fall on Zyprexa generic competition
25 October 2012
FDA clears new use for Eli Lilly's Alimta
19 October 2012
Eli Lilly's ramucirumab succeeds in Ph III gastric cancer study
16 October 2012
Roche and Lilly drugs chosen for major Washington University Alzheimer's prevention trial
11 October 2012
New uses of Cialis, Votubia, Galvus, Eucreas and Eliquis backed by CHMP, but not Qsiva
24 September 2012
Discontinuation of dalcetrapib leaves Merck's anacetrapib as the front-running novel CETP inhibitor for dyslipidemia
20 September 2012
Top drugmakers set up non-profit TransCelerate to speed pharma R&D
20 September 2012
STEMI guidelines now recommend AstraZeneca's ticagrelor as first-line treatment option
30 August 2012
US genericization of clopidogrel will initially contract ACS market, before uptake of novel oral agents lifts sector to $2.7 billion
27 August 2012
AstraZeneca and Bristol-Myers complete diabetes alliance expansion; Lilly revises guidance
10 August 2012
Eli Lilly 2nd-qtr sales and earnings tumble on Zyprexa patent expiry, but still beat forecasts
26 July 2012
Amylin seduced by $5.3 billion bid from Bristol-Myers; AstraZeneca chips in for share of the action
2 July 2012
More news from American Diabetes Association meeting
13 June 2012
Highlights of American Diabetes Association meeting
11 June 2012
More news from ASCO meeting
5 June 2012
Thought leaders indicate Benlysta has advantages over market leader CellCept for Lupus
26 April 2012
Vanda gains rights to Lilly's NK-1 receptor antagonist
17 April 2012
UK NICE says yes to Lilly’s Bydureon and ALK-Abello’s Pharmalgen
22 February 2012
Proposal to fund Lilly’s Effient in New Zealand
21 February 2012
EMA advisory backs Humira for UC and expanded use of Byetta
20 February 2012
FDA approves combo diabetes drug Jentadueto and Kalydeco
1 February 2012
Eli Lilly results hammered by Zyprexa patent loss
1 February 2012
FDA finally approves Bydureon
30 January 2012
ShangPharma milestone in Hengrui accord; expands Lilly contract
23 January 2012
Mixed NICE recommendations for CML and diabetes drugs
13 January 2012
Added benefit of Trajenta not proven, says German agency
10 January 2012
Eli Lilly falls as 2012 forecasts disappoint
6 January 2012
ImmunoGen inks ADC cancer deal with Lilly
21 December 2011
Eli Lilly initiates first international, observational study to understand barriers to progression of insulin treatment
2 December 2011
Brazilian acute coronary syndrome drug market set to nearly double to $229 million in 2015
1 December 2011
Global pain management drugs market to see moderate growth as generic share continues to rise
24 November 2011
China’s acute coronary syndrome drug market forecast to grow to nearly $450 million in 2015
22 November 2011
Despite generics for two key drugs, neuropathic pain market will grow to $8.4 billion in 2020
13 November 2011
Amylin diabetes drug exenatide deal with Eli Lilly terminated, with $1.45 billion settlement to Lilly
9 November 2011
Amylin and Lilly’s diabetes drug Byetta has rapid, powerful anti-inflammatory effect
4 November 2011
Appropriate assessment of both benefits and risks critical in US regulatory process, says Lilly CEO
2 November 2011
Eli Lilly 3rd-qtr 2011 sales grow 9% but costs hit profits
21 October 2011
Lilly’s Cialis meets endpoints in Ph III study in men with both erectile dysfunction and BPH
13 October 2011
In India, Lilly and Boehringer link for diabetes drug marketing; GSK eyeing acquisitions
4 October 2011
Lilly’s Alimta shows benefit in hard-to-treat lung cancer patients
28 September 2011
URMC research shows Lilly’s Forteo could extend life of arthritic joints
22 September 2011
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
